NOTE, original article title: Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

In the ALLEGRO trial, adults with alopecia areata were randomized to ritlecitinib (n = 48), brepocitinib (n = 47) or placebo (n = 47), and this analysis was conducted to report scores from the Alopecia Areata Symptom Impact Scale (AASIS; a patient-reported outcome tool) as well as to examine the associations of those scores with clinician-evaluated Severity of Alopecia Tool (SALT) scores at baseline and week 24 of the ALLEGRO trial.

• Treatment groups had similar baseline AASIS and SALT scores.

• At week 24, significantly improved AASIS and SALT scores were seen in patients randomized to ritlecitinib or brepocitinib, vs placebo.

• Improvements in the mean SALT scores (standard deviation) relative to baseline were evident at week 24 [ritlecitinib, 54.4 (40.3) vs 89.4 (15.8); brepocitinib, 31.9 (35.7) vs 86.4 (18.1)].

• At week 24, medium-to-large correlations can be observed between AASIS global and subscale scores and SALT scores.

• Overall, new patient-reported outcome tools are required to correctly evaluate patients' relevant alopecia areata associated signs, symptoms and daily functioning.